Lysophosphatidic acid and renal fibrosis

Biochimica et Biophysica Acta - Molecular and Cell Biology of Lipids

Volumn 1781, Issue 9, 2008, Pages 582-587

  Pradère, Jean Philippe ^a,b   Gonzalez, Julien ^a,b   Klein, Julie ^a,b   Valet, Philippe ^a,b   Grès, Sandra ^a,b   Salant, David ^c   Bascands, Jean Loup ^a,b   Saulnier Blache, Jean Sébastien ^a,b   Schanstra, Joost P ^a,b  

^a INSERM   (France)

^b UNIVERSITÉ DE TOULOUSE   (France)

^c BOSTON UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Fibrosis; Kidney; Lysophosphatidic acid; Receptor

Indexed keywords

CONNECTIVE TISSUE GROWTH FACTOR; G PROTEIN COUPLED RECEPTOR; LYSOPHOSPHATIDIC ACID; LYSOPHOSPHATIDIC ACID 1 RECEPTOR; LYSOPHOSPHATIDIC ACID RECEPTOR; PHOSPHOLIPID; UNCLASSIFIED DRUG;

CELL STIMULATION; DISEASE ASSOCIATION; DISEASE COURSE; FIBROBLAST; FIBROSIS; HUMAN; IN VIVO STUDY; KIDNEY FIBROSIS; KIDNEY PROXIMAL TUBULE; LIPID ANALYSIS; LUNG FIBROSIS; MACROPHAGE; MESANGIUM CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW; VASCULAR LESION;

ANIMALS; FIBROSIS; HUMANS; KIDNEY DISEASES; LYSOPHOSPHOLIPIDS; MODELS, BIOLOGICAL; RECEPTORS, LYSOPHOSPHATIDIC ACID;

EID: 50149099150     PISSN: 13881981     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbalip.2008.04.001     Document Type: Review

References (68)

1. Meguid El Nahas A., and Bello A.K. Chronic kidney disease: the global challenge. Lancet 365 (2005) 331-340
2. Boor P., Sebekova K., Ostendorf T., and Floege J. Treatment targets in renal fibrosis. Nephrol. Dial. Transplant 22 (2007) 3391-3407
3. Strutz F. Potential methods to prevent interstitial fibrosis in renal disease. Expert Opin. Investig. Drugs 10 (2001) 1989-2001
4. Bascands J.L., and Schanstra J.P. Obstructive nephropathy: insights from genetically engineered animals. Kidney Int. 68 (2005) 925-937
5. Iwano M., and Neilson E.G. Mechanisms of tubulointerstitial fibrosis. Curr. Opin. Nephrol. Hypertens 13 (2004) 279-284
6. Basile D.P. The transforming growth factor beta system in kidney disease and repair: recent progress and future directions. Curr. Opin. Nephrol. Hypertens 8 (1999) 21-30
7. Wynn T.A. Common and unique mechanisms regulate fibrosis in various fibroproliferative diseases. J. Clin. Invest. 117 (2007) 524-529
8. Watterson K.R., Lanning D.A., Diegelmann R.F., and Spiegel S. Regulation of fibroblast functions by lysophospholipid mediators: potential roles in wound healing. Wound Repair Regen. 15 (2007) 607-616
9. Ruiz-Ortega M., Bustos C., Plaza J.J., and Egido J. Overexpression of extracellular matrix proteins in renal tubulointerstitial cells by platelet-activating-factor stimulation. Nephrol. Dial. Transplant 13 (1998) 886-892
10. Ruiz-Ortega M., Largo R., Bustos C., Gomez-Garre D., and Egido J. Platelet-activating factor stimulates gene expression and synthesis of matrix proteins in cultured rat and human mesangial cells: role of TGF-beta. J. Am. Soc. Nephrol. 8 (1997) 1266-1275
11. Doi K., Okamoto K., Negishi K., Suzuki Y., Nakao A., Fujita T., Toda A., Yokomizo T., Kita Y., Kihara Y., Ishii S., Shimizu T., and Noiri E. Attenuation of folic acid-induced renal inflammatory injury in platelet-activating factor receptor-deficient mice. Am. J. Pathol. 168 (2006) 1413-1424
12. Giri S.N., Sharma A.K., Hyde D.M., and Wild J.S. Amelioration of bleomycin-induced lung fibrosis by treatment with the platelet activating factor receptor antagonist WEB 2086 in hamsters. Exp. Lung Res. 21 (1995) 287-307
13. Kuroda K., Morimoto Y., Ogami A., Oyabu T., Nagatomo H., Hirohashi M., Yamato H., Nagafuchi Y., and Tanaka I. Phospholipid concentration in lung lavage fluid as biomarker for pulmonary fibrosis. Inhal. Toxicol. 18 (2006) 389-393
14. Yasuda K., Sato A., Nishimura K., Chida K., and Hayakawa H. Phospholipid analysis of alveolar macrophages and bronchoalveolar lavage fluid following bleomycin administration to rabbits. Lung 172 (1994) 91-102
15. Adrian J.E., Poelstra K., Scherphof G.L., Meijer D.K., van Loenen-Weemaes A.M., Reker-Smit C., Morselt H.W., Zwiers P., and Kamps J.A. Effects of a new bioactive lipid-based drug carrier on cultured hepatic stellate cells and liver fibrosis in bile duct-ligated rats. J. Pharmacol. Exp. Ther. 321 (2007) 536-543
16. Anliker B., and Chun J. Cell surface receptors in lysophospholipid signaling. Semin. Cell Dev. Biol. 15 (2004) 457-465
17. Ohta H., Sato K., Murata N., Damirin A., Malchinkhuu E., Kon J., Kimura T., Tobo M., Yamazaki Y., Watanabe T., Yagi M., Sato M., Suzuki R., Murooka H., Sakai T., Nishitoba T., Im D.S., Nochi H., Tamoto K., Tomura H., and Okajima F. Ki16425, a subtype-selective antagonist for EDG-family lysophosphatidic acid receptors. Mol. Pharmacol. 64 (2003) 994-1005
18. Boucharaba A., Serre C.M., Guglielmi J., Bordet J.C., Clezardin P., and Peyruchaud O. The type 1 lysophosphatidic acid receptor is a target for therapy in bone metastases. Proc. Natl. Acad. Sci. U. S. A. 103 (2006) 9643-9648
19. Contos J.J., Fukushima N., Weiner J.A., Kaushal D., and Chun J. Requirement for the lpA1 lysophosphatidic acid receptor gene in normal suckling behavior. Proc. Natl. Acad. Sci. U. S. A. 97 (2000) 13384-13389
20. Contos J.J., Ishii I., Fukushima N., Kingsbury M.A., Ye X., Kawamura S., Brown J.H., and Chun J. Characterization of lpa(2) (Edg4) and lpa(1)/lpa(2) (Edg2/Edg4) lysophosphatidic acid receptor knockout mice: signaling deficits without obvious phenotypic abnormality attributable to lpa(2). Mol. Cell Biol. 22 (2002) 6921-6929
21. Ye X., Hama K., Contos J.J., Anliker B., Inoue A., Skinner M.K., Suzuki H., Amano T., Kennedy G., Arai H., Aoki J., and Chun J. LPA3-mediated lysophosphatidic acid signalling in embryo implantation and spacing. Nature 435 (2005) 104-108
22. Gardell S.E., Dubin A.E., and Chun J. Emerging medicinal roles for lysophospholipid signaling. Trends Mol. Med. 12 (2006) 65-75
23. Vial C., Zuniga L.M., Cabello-Verrugio C., Canon P., Fadic R., and Brandan E. Skeletal muscle cells express the profibrotic cytokine connective tissue growth factor (CTGF/CCN2), which induces their dedifferentiation. J. Cell Physiol. (2007)
24. Chudgar S.M., Deng P., Maddala R., Epstein D.L., and Rao P.V. Regulation of connective tissue growth factor expression in the aqueous humor outflow pathway. Mol. Vis. 12 (2006) 1117-1126
25. Eberlein M., Heusinger-Ribeiro J., and Goppelt-Struebe M. Rho-dependent inhibition of the induction of connective tissue growth factor (CTGF) by HMG CoA reductase inhibitors (statins). Br. J. Pharmacol. 133 (2001) 1172-1180
26. Graness A., Giehl K., and Goppelt-Struebe M. Differential involvement of the integrin-linked kinase (ILK) in RhoA-dependent rearrangement of F-actin fibers and induction of connective tissue growth factor (CTGF). Cell Signal 18 (2006) 433-440
27. Graness A., Poli V., and Goppelt-Struebe M. STAT3-independent inhibition of lysophosphatidic acid-mediated upregulation of connective tissue growth factor (CTGF) by cucurbitacin I. Biochem. Pharmacol. 72 (2006) 32-41
28. Hahn A., Heusinger-Ribeiro J., Lanz T., Zenkel S., and Goppelt-Struebe M. Induction of connective tissue growth factor by activation of heptahelical receptors. Modulation by Rho proteins and the actin cytoskeleton. J. Biol. Chem. 275 (2000) 37429-37435
29. Heusinger-Ribeiro J., Eberlein M., Wahab N.A., and Goppelt-Struebe M. Expression of connective tissue growth factor in human renal fibroblasts: regulatory roles of RhoA and cAMP. J. Am. Soc. Nephrol. 12 (2001) 1853-1861
30. Muehlich S., Schneider N., Hinkmann F., Garlichs C.D., and Goppelt-Struebe M. Induction of connective tissue growth factor (CTGF) in human endothelial cells by lysophosphatidic acid, sphingosine-1-phosphate, and platelets. Atherosclerosis 175 (2004) 261-268
31. Pradere J.P., Klein J., Gres S., Guigne C., Neau E., Valet P., Calise D., Chun J., Bascands J.L., Saulnier-Blache J.S., and Schanstra J.P. LPA1 receptor activation promotes renal interstitial fibrosis. J. Am. Soc. Nephrol. 18 (2007) 3110-3118
32. Wiedmaier N., Muller S., Koberle M., Manncke B., Krejci J., Autenrieth I.B., and Bohn E. Bacteria induce CTGF and CYR61 expression in epithelial cells in a lysophosphatidic acid receptor-dependent manner. Int. J. Med. Microbiol. (2007)
33. Leask A., and Abraham D.J. TGF-beta signaling and the fibrotic response. Faseb. J. 18 (2004) 816-827
34. Kantarci A., Black S.A., Xydas C.E., Murawel P., Uchida Y., Yucekal-Tuncer B., Atilla G., Emingil G., Uzel M.I., Lee A., Firatli E., Sheff M., Hasturk H., Van Dyke T.E., and Trackman P.C. Epithelial and connective tissue cell CTGF/CCN2 expression in gingival fibrosis. J. Pathol. 210 (2006) 59-66
35. Ikeda H., Yatomi Y., Yanase M., Satoh H., Nishihara A., Kawabata M., and Fujiwara K. Effects of lysophosphatidic acid on proliferation of stellate cells and hepatocytes in culture. Biochem. Biophys. Res. Commun. 248 (1998) 436-440
36. Wu J., and Zern M.A. Hepatic stellate cells: a target for the treatment of liver fibrosis. J. Gastroenterol. 35 (2000) 665-672
37. Watanabe N., Ikeda H., Nakamura K., Ohkawa R., Kume Y., Tomiya T., Tejima K., Nishikawa T., Arai M., Yanase M., Aoki J., Arai H., Omata M., Fujiwara K., and Yatomi Y. Plasma lysophosphatidic acid level and serum autotaxin activity are increased in liver injury in rats in relation to its severity. Life Sci. 81 (2007) 1009-1015
38. Watanabe N., Ikeda H., Nakamura K., Ohkawa R., Kume Y., Aoki J., Hama K., Okudaira S., Tanaka M., Tomiya T., Yanase M., Tejima K., Nishikawa T., Arai M., Arai H., Omata M., Fujiwara K., and Yatomi Y. Both plasma lysophosphatidic acid and serum autotaxin levels are increased in chronic hepatitis C. J. Clin. Gastroenterol. 41 (2007) 616-623
39. Tager A.M., Lacamera P., Shea B.S., Campanella G.S., Selman M., Zhao Z., Polosukhin V., Wain J., Karimi-Shah B.A., Kim N.D., Hart W.K., Pardo A., Blackwell T.S., Xu Y., Chun J., and Luster A.D. The lysophosphatidic acid receptor LPA(1) links pulmonary fibrosis to lung injury by mediating fibroblast recruitment and vascular leak. Nat. Med. (2007)
40. de Vries B., Matthijsen R.A., van Bijnen A.A., Wolfs T.G., and Buurman W.A. Lysophosphatidic acid prevents renal ischemia-reperfusion injury by inhibition of apoptosis and complement activation. Am. J. Pathol. 163 (2003) 47-56
41. Okusa M.D., Ye H., Huang L., Sigismund L., Macdonald T., and Lynch K.R. Selective blockade of lysophosphatidic acid LPA3 receptors reduces murine renal ischemia-reperfusion injury. Am. J. Physiol. Renal. Physiol. 285 (2003) F565-F574
42. Sasagawa T., Suzuki K., Shiota T., Kondo T., and Okita M. The significance of plasma lysophospholipids in patients with renal failure on hemodialysis. J. Nutr. Sci. Vitaminol. (Tokyo). 44 (1998) 809-818
43. Akalaev R.N., and Abidov A.A. [Phospholipid composition of erythrocytes in patients with chronic kidney failure]. Vopr. Med. Khim. 39 (1993) 43-45
44. Kamanna V.S., Bassa B.V., Ganji S.H., and Roh D.D. Bioactive lysophospholipids and mesangial cell intracellular signaling pathways: role in the pathobiology of kidney disease. Histol. Histopathol. 20 (2005) 603-613
45. Levine J.S., Koh J.S., Triaca V., and Lieberthal W. Lysophosphatidic acid: a novel growth and survival factor for renal proximal tubular cells. Am. J. Physiol. 273 (1997) F575-F585
46. Gaits F., Salles J.P., and Chap H. Dual effect of lysophosphatidic acid on proliferation of glomerular mesangial cells. Kidney Int. 51 (1997) 1022-1027
47. Inoue C.N., Forster H.G., and Epstein M. Effects of lysophosphatidic acid, a novel lipid mediator, on cytosolic Ca2+ and contractility in cultured rat mesangial cells. Circ. Res. 77 (1995) 888-896
48. Inoue C.N., Ko Y.H., Guggino W.B., Forster H.G., and Epstein M. Lysophosphatidic acid and platelet-derived growth factor synergistically stimulate growth of cultured rat mesangial cells. Proc. Soc. Exp. Biol. Med. 216 (1997) 370-379
49. Goppelt-Struebe M., Hahn A., Iwanciw D., Rehm M., and Banas B. Regulation of connective tissue growth factor (ccn2; ctgf) gene expression in human mesangial cells: modulation by HMG CoA reductase inhibitors (statins). Mol. Pathol. 54 (2001) 176-179
50. Dixon R.J., and Brunskill N.J. Lysophosphatidic acid-induced proliferation in opossum kidney proximal tubular cells: role of PI 3-kinase and ERK. Kidney Int. 56 (1999) 2064-2075
51. Dixon R.J., Young K., and Brunskill N.J. Lysophosphatidic acid-induced calcium mobilization and proliferation in kidney proximal tubular cells. Am. J. Physiol. 276 (1999) F191-F198
52. Choi J.W., Lee-Kwon W., Jeon E.S., Kang Y.J., Kawano K., Kim H.S., Suh P.G., Donowitz M., and Kim J.H. Lysophosphatidic acid induces exocytic trafficking of Na(+)/H(+) exchanger 3 by E3KARP-dependent activation of phospholipase C. Biochim. Biophys. Acta. 1683 (2004) 59-68
53. Lee-Kwon W., Kawano K., Choi J.W., Kim J.H., and Donowitz M. Lysophosphatidic acid stimulates brush border Na+/H+ exchanger 3 (NHE3) activity by increasing its exocytosis by an NHE3 kinase A regulatory protein-dependent mechanism. J. Biol. Chem. 278 (2003) 16494-16501
54. Kumagai N., Inoue C.N., Kondo Y., and Iinuma K. Mitogenic action of lysophosphatidic acid in proximal tubular epithelial cells obtained from voided human urine. Clin. Sci. (Lond). 99 (2000) 561-567
55. Simon M.F., Daviaud D., Pradere J.P., Gres S., Guigne C., Wabitsch M., Chun J., Valet P., and Saulnier-Blache J.S. Lysophosphatidic acid inhibits adipocyte differentiation via lysophosphatidic acid 1 receptor-dependent down-regulation of peroxisome proliferator-activated receptor gamma2. J. Biol. Chem. 280 (2005) 14656-14662
56. Chevalier R.L. Obstructive nephropathy: towards biomarker discovery and gene therapy. Nat. Clin. Pract. Nephrol. 2 (2006) 157-168
57. Klahr S., and Morrissey J. Obstructive nephropathy and renal fibrosis. Am. J. Physiol. Renal. Physiol. 283 (2002) F861-F875
58. Koh J.S., Lieberthal W., Heydrick S., and Levine J.S. Lysophosphatidic acid is a major serum noncytokine survival factor for murine macrophages which acts via the phosphatidylinositol 3-kinase signaling pathway. J. Clin. Invest. 102 (1998) 716-727
59. Llodra J., Angeli V., Liu J., Trogan E., Fisher E.A., and Randolph G.J. Emigration of monocyte-derived cells from atherosclerotic lesions characterizes regressive, but not progressive, plaques. Proc. Natl. Acad. Sci. U. S. A. 101 (2004) 11779-11784
60. Haverty T.P., Kelly C.J., Hines W.H., Amenta P.S., Watanabe M., Harper R.A., Kefalides N.A., and Neilson E.G. Characterization of a renal tubular epithelial cell line which secretes the autologous target antigen of autoimmune experimental interstitial nephritis. J. Cell. Biol. 107 (1988) 1359-1368
61. Yokoi H., Mukoyama M., Nagae T., Mori K., Suganami T., Sawai K., Yoshioka T., Koshikawa M., Nishida T., Takigawa M., Sugawara A., and Nakao K. Reduction in connective tissue growth factor by antisense treatment ameliorates renal tubulointerstitial fibrosis. J. Am. Soc. Nephrol. 15 (2004) 1430-1440
62. Yokoi H., Mukoyama M., Sugawara A., Mori K., Nagae T., Makino H., Suganami T., Yahata K., Fujinaga Y., Tanaka I., and Nakao K. Role of connective tissue growth factor in fibronectin expression and tubulointerstitial fibrosis. Am. J. Physiol. Renal. Physiol. 282 (2002) F933-F942
63. Nagatoya K., Moriyama T., Kawada N., Takeji M., Oseto S., Murozono T., Ando A., Imai E., and Hori M. Y-27632 prevents tubulointerstitial fibrosis in mouse kidneys with unilateral ureteral obstruction. Kidney Int. 61 (2002) 1684-1695
64. Moolenaar W.H., van Meeteren L.A., and Giepmans B.N. The ins and outs of lysophosphatidic acid signaling. Bioessays 26 (2004) 870-881
65. Fukuzaki A., Morrissey J., and Klahr S. Enhanced glomerular phospholipase activity in the obstructed kidney. Int. Urol. Nephrol. 27 (1995) 783-790
66. Lloyd C.M., Minto A.W., Dorf M.E., Proudfoot A., Wells T.N., Salant D.J., and Gutierrez-Ramos J.C. RANTES and monocyte chemoattractant protein-1 (MCP-1) play an important role in the inflammatory phase of crescentic nephritis, but only MCP-1 is involved in crescent formation and interstitial fibrosis. J. Exp. Med. 185 (1997) 1371-1380
67. Zeisberg M., Hanai J., Sugimoto H., Mammoto T., Charytan D., Strutz F., and Kalluri R. BMP-7 counteracts TGF-beta1-induced epithelial-to-mesenchymal transition and reverses chronic renal injury. Nat. Med. 9 (2003) 964-968
68. Shull M.M., Ormsby I., Kier A.B., Pawlowski S., Diebold R.J., Yin M., Allen R., Sidman C., Proetzel G., Calvin D., et al. Targeted disruption of the mouse transforming growth factor-beta 1 gene results in multifocal inflammatory disease. Nature 359 (1992) 693-699